6 analysts have shared their evaluations of Opus Genetics (NASDAQ:IRD) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

Abstract: With the fast development of advanced communication systems, wideband low-noise amplifiers (LNAs) have become more and more critical as they determine the overall performance of the ...

Shares of Rayonier Advanced Materials rose after the company appointed Scott Sutton, former chief executive of Olin Corp., as its new CEO. The stock jumped 19% to $6.98. It is down 14% over the past ...

Zydus Lifesciences Limited ( (IN:ZYDUSLIFE)) has issued an announcement. Zydus Lifesciences has signed an exclusive agreement with US-based Myriad Genetics to introduce a suite of advanced cancer-risk ...

For how to get started check out the wiki page! This mod does not add any power gen as of writing this, so you will need to have another mod that generates FE(Forge Energy) power such as Extra ...

Elon Musk’s artificial-intelligence company, xAI, is in advanced talks to raise $15 billion in new equity at a $230 billion valuation, according to people familiar with the plans. The new valuation ...

Prostate cancer advancements highlight genetic mutations' impact on therapy and family health, emphasizing early treatment strategies for better outcomes. In recognition of September as Prostate ...

The U.S. Navy has awarded Northrop Grumman a $140.8 million modification to a contract the company secured in 2018 for the E-2D Advanced Hawkeye program. Join the 2025 Navy Summit, where top-tier Navy ...

In this tutorial, we demonstrate how to combine the power of SerpAPI’s Google search capabilities with Google’s Gemini-1.5-Flash model to create an advanced, end-to-end research and analysis workflow ...

Development and validation of a novel circulating tumor cell response stratification criteria for metastatic castration-resistant prostate cancer clinical trials. This is an ASCO Meeting Abstract from ...

- FDA RMAT designation recognizes encouraging early data from Opus’ Phase 1/2 trial in patients with LCA5, an ultra-rare inherited retinal disease RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE ...